Celgene Corporation (CELGZ) stock prices updated...
 

Celgene Corporation stock price

Celgene Corporation latest news:


  • 01/30/2018 12:35:00

    Celgene Looking Good With Plans for More Growth

    The biotech's partnerships and acquisitions are about to start paying off.

  • 01/29/2018 09:05:36

    Celgene chairman to retire after 2 years in the role

    Celgene Corp. said Monday Chairman Bob Hugin will retire, effective Feb. 5, after about two years in the role and 19 years with the company. The biopharmaceutical company said Chief Executive Mark Alles will take on the additional role of chairman in Hugin's place. Hugin was appointed chairman on March 1, 2016. He had joined the company in June 1999 as chief financial officer. The stock fell 1% in morning trade. It has lost 8.3% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has rallied 30.2% and the S&P 500 has climbed 24.5%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/29/2018 09:02:32

    BRIEF-Celgene Announces Retirement Of Executive Chairman Bob Hugin

    Celgene Corp(CELG): * CELGENE ANNOUNCES RETIREMENT OF EXECUTIVE CHAIRMAN BOB HUGIN AND APPOINTMENT OF CEO MARK ALLES AS CHAIRMAN OF THE BOARD OF DIRECTORS.

  • 01/26/2018 15:35:43

    BRIEF-Celgene Says Entered Into Settlement With Actavis​

    Celgene Corp(CELG): * CELGENE(CELG) - ENTERED INTO SETTLEMENT WITH ACTAVIS LLC TO TERMINATE PENDING PATENT LITIGATION, IPR CHALLENGES RELATING TO CERTAIN PATENTS FOR ABRAXANE​. * CELGENE (CELG) - TO GIVE ACTAVIS LICENSE TO PATENTS TO MANUFACTURE, SELL GENERIC PACLITAXEL PROTEIN-BOUND PARTICLES IN U.S. FROM MARCH 31, 2022 Source text - http://bit.ly/2EcZicz Further company coverage:

  • 01/25/2018 21:01:50

    Asian shares recoup losses, dollar steady as eyes on Trump

    U.S. stocks are mixed Thursday morning as health care companies including Biogen and Celgene rise, but airlines continue to take steep losses as investors worry about rising costs and the possibility of falling fares.

  • 01/25/2018 13:46:31

    US stocks slip as homebuilders, retailers and airlines skid

    U.S. stocks are mixed Thursday morning as health care companies including Biogen and Celgene rise, but airlines continue to take steep losses as investors worry about rising costs and the possibility of falling fares.

  • 01/25/2018 10:53:40

    Technology companies and drugmakers lead stocks higher

    U.S. stocks are mixed Thursday morning as health care companies including Biogen and Celgene rise, but airlines continue to take steep losses as investors worry about rising costs and the possibility of falling fares.

  • 01/25/2018 05:53:33

    Celgene's stock gains after profit beats expectations

    Shares of Celgene Corp. rallied 1.7% in premarket trade Thursday, after the biopharmaceutical company reported a fourth-quarter profit that rose above expectations. The company swung to a net loss of $81 million, or 10 cents a share, in the quarter to Dec. 31, from a profit of $429 million, or 53 cents a share, in the same period a year ago. Excluding non-recurring items, such as the one-time effect of the tax-reform legislation, adjusted earnings per share rose to $2.00 from $1.61, beating the FactSet consensus of $1.97. Revenue increased to $3.48 billion from $2.98 billion, in line with the FactSet consensus of $3.47 billion, as 21% growth in sales of its blockbuster cancer treatment Revlimid to $2.2 billion matched expectations. For 2018, the company expects revenue of $14.4 billion to $14.8 billion, compared with the FactSet consensus of $14.8 billion, while the adjusted EPS outlook of $8.70 to $8.90 was above expectations of $8.63. Earlier this week, Celgene announced a deal to buy Juno Therapeutics Inc. for about $9 billion. The stock has tumbled 13.8% over the past three months, while the iShares Nasdaq Biotechnology ETF has climbed 8.2% and the S&P 500 has gained 11%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/22/2018 15:17:27

    Celgene to buy Juno for $9 billion

    Celgene announced a $9 billion cash buyout of Juno Therapeutics as it moves to cement its position as a key player in a new range of cancer therapies. Aleksandra Michalska reports. Video provided by Reuters        

  • 01/22/2018 09:03:35

    WRAPUP 2-Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    * Large drugmakers scour for products from smaller biotechs (Adds detail on gains in other biotech shares)

  • 01/22/2018 08:57:16

    Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    LONDON, Jan 22 (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets.

  • 01/22/2018 08:10:55

    Why Celgene Is Betting Big on 2020 With Juno Acquisition


  • 01/22/2018 07:32:45

    U.S. stocks open slightly lower in first trading day of government shutdown

    U.S. stocks fell modestly at the open on Monday, as investors found few reasons to keep pushing shares higher following a push to repeated records, and as the government shutdown provided another element of uncertainty to markets. The Dow Jones Industrial Average fell 72 points, or 0.2%, to 26,011. The S&P 500 declined 1 point to 2,809, a drop of less than 0.1%. The Nasdaq Composite Index was unchanged at 7,336. Both the S&P and the Nasdaq are coming off closing records, while the Dow is close to its own peak. While government shutdowns have historically not been big selling catalysts, uncertainty over when the government would reopened appeared to dampen buying enthusiasm. The Senate was expected to hold a procedural vote at noon Eastern Time on a measure that would keep the government funded through Feb. 8, but it wasn't clear if it would have enough support to advance. In company news, Juno Therapeutics Inc. jumped 27% after Celgene Corp. agreed to buy the company for $9 billion. Bioverativ Inc. soared 63% after Sanofi SA said it would buy it for $12 billion.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/22/2018 04:55:56

    Deals of the day-Mergers and acquisitions

    The following bids, mergers, acquisitions. ** Celgene Corp (CELG) said it agreed to buy rest of Juno Therapeutics Inc (JUNO) for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.

  • 01/17/2018 14:35:29

    Juno and Boeing climb while Goldman Sachs and GE drop

    Stocks that moved substantially or traded heavily Wednesday: Juno Therapeutics Inc., up $23.65 to $69.25 The Wall Street Journal reported that biotech drugmaker Celgene may buy the cancer therapy company.

  • 01/16/2018 15:08:49

    Celgene in talks to buy Juno Therapeutics - WSJ

    Celgene Corp(CELG) is in talks to buy Juno Therapeutics Inc (JUNO), the Wall Street Journal reported, citing sources familiar with the matter. Shares of Juno, which has a market value of $5.57 billion, were up 36 percent at $62.50 in extended trading on Tuesday.

  • 01/16/2018 14:51:17

    Celgene in talks to buy Juno Therapeutics: report

    Celgene Corp. is in talks to buy Juno Therapeutics Inc. , according to a report on The Wall Street Journal Tuesday that cited unnamed sources. Juno is a biotech company developing cancer treatments. Juno stock soared more than 30% in late trading Tuesday and ended the regular trading day down 6.5%. Celgene shares rose 1% and closed the regular session down 1.1%. Celgene earlier this month released preliminary fourth-quarter and full-year 2017 results and provided a downbeat outlook for 2018. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/08/2018 09:41:17

    Health-care ETF tumbles as biotechnology stocks weigh

    The largest exchange-traded fund to track the health-care sector fell on Monday, dropping as the biggest declining industry of the day by far. The Health Care Select Sector SPDR ETF was down 0.8%, its biggest one-day percentage drop since Dec. 14. The fund is coming off a four-day rally, and it hit a record on Friday. Biotechnology companies were the biggest drags on the sector on Monday. Celgene Corp. fell 3.2% after it agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $7 billion. Separately, Biogen Inc. shares fell 3.9% while those for Regeneron Pharmaceuticals was down 3.1%. The iShares Nasdaq Biotechnology ETF fell 0.8% on Monday. Thus far this year, the health-care fund is up 2.3%, compared with the 2.6% rise of the S&P 500 . The S&P was unchanged in Monday trading.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/08/2018 09:28:33

    BRIEF-Celgene CEO Says Plans To Invest Heavily In R&D In 2018

    * CELGENE CEO SAYS PLANS TO INVEST HEAVILY IN RESEARCH AND DEVELOPMENT, BUSINESS DEVELOPMENT IN 2018

  • 01/07/2018 18:20:00

    Celgene to buy Impact Biomedicines for up to $7 billion

    U.S. biotech pharmaceutical firm Celgene Corp (CELG) said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.

  • 12/28/2017 18:39:00

    Here's Where Things Went Wrong for Celgene Corporation in 2017

    Here's a look at why the big biotech's shares cratered late in 2017.

  • 12/27/2017 14:07:25

    U.S. stocks log modest gains, buoyed by health-care, tech, real-estate shares

    U.S. stock benchmarks logged slight gains on Wednesday, helping to halt a two-day skid for equities. However, volumes were seasonally low and activity muted as investors are reluctant to make big bets with just a few trading days remaining in 2017. The Dow Jones Industrial Average ended up about 28 points, or 0.1%, at 24,774, the S&P 500 index finished up 2 points, or 0.1%, at 2,682. Gains in health care, up 0.2%, technology, up 0.2%, and real-estate, 0.4% higher, helped to offset losses in energy, down 0.3%, as crude-oil prices retreated from a 2 1/2-year high. Meanwhile the Nasdaq Composite Index edged up 3 points, or less than 0.1%, to 6,939. The advances were enough to avoid a three-session skid for the major benchmarks, which would have been the longest in three months. In corporate news, shares of Celgene Corp. ended down 2.4% after its shares were downgraded to market perform by Bernstein. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/27/2017 11:32:52

    Celgene shares slide 2% after Bernstein downgrade

    Shares of biotech Celgene Corp. slid 2% Wednesday, after Bernstein downgraded them to market perform and said pipeline setbacks have crushed much of the stock's potential upside. Celgene said last week a trial of cancer treatment Revlimid as a treatment for follicular lymphoma failed to meet its main goals. The drug, which currently accounts for $8.2 billion of Celgene's sales, was expected to grow to $13.8 billion by 2023, partly because of its use in treating that condition. "We were quite bullish on this potential, modeling $16B by 2022 (of which $3-$4B were for follicular lymphoma)," Bernstein analysts wrote in a note. The news comes after Celgene announced plans to abandon 3 clinical trials for its GED-0301 therapy in Crohn's disease, shedding a part of its inflammation and immunology portfolio that was viewed as having strong potential. Celgene paid $710 million upfront for GED-0301 in 2014 - making the decision a major blow. "Part of the excitement around Celgene is the 'bet on innovation'- CELG focuses on identifying promising targets early and is not afraid to invest heavily to obtain them," wrote Bernstein analysts. "However, some of that shine has eroded recently." Celgene shares have fallen 9% in 2017, while the S&P 500 has gained about 20%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/22/2017 09:43:11

    US STOCKS-UnitedHealth, Nike weigh on Dow

    * Celgene falls after follicular lymphoma regimen fails trial

  • 12/21/2017 14:44:21

    Celgene stock falls after Revlimid cancer study fails

    Celgene Corp. shares declined more than 4% in late trading Thursday after revealing that a phase II study of a cancer drug failed to meet its goal. Celgene said that a study testing Revlimid on follicular lymphoma did not meet the desired endpoint. Revlimid is already approved for other forms of cancer, and is Celgene's biggest drug in terms of revenue, producing $7 billion in sales in 2016 before price hikes last year. "We remain committed to advancing our broad pipeline of novel therapies to establish new standards of care for patients with lymphoma," Chief Medical Officer Jay Backstrom said in the announcement. Celgene stock fell to $103.50 in late trading, after closing with a 0.4% decline at $107.88.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Celladon CorporationCLDN | Celldex Therapeutics, Inc.CLDX | Cellectar Biosciences, Inc.CLRB | Cellectar Biosciences, Inc.CLRBW | Cellectis S.A.CLLS | Cellular Biomedicine Group, Inc.CBMG | Celsion CorporationCLSN | Celsus Therapeutics PlcCLTX | Celyad SACYAD | Cempra, Inc.CEMP |